Gm597 Activators
Chemical activators of Spata31e5 engage various signaling pathways and cellular processes to enhance the functional activity of the protein. Forskolin, by activating adenylate cyclase, increases intracellular cAMP levels, which in turn activate PKA. PKA then potentially phosphorylates targets within Spata31e5's pathway, enhancing its functional activity. Similarly, IBMX prevents the degradation of cAMP and cGMP, indirectly facilitating the activation of PKA and PKG, which can also lead to the enhanced functional activity of Spata31e5 through phosphorylation mechanisms.
PMA's activation of PKC and ionomycin's increase in intracellular calcium levels both have the potential to activate proteins and signaling pathways that are associated with Spata31e5's function. The activation of these pathways may lead to a cascade of events that ultimately enhance the functional activity of Spata31e5. LY294Chemical activators of spermatogenesis associated 31 subfamily E member 5 (Spata31e5) stimulate signaling pathways and modify cellular processes to augment the functional activity of this protein. Forskolin triggers adenylate cyclase, leading to a rise in intracellular cAMP, which activates protein kinase A (PKA). The activated PKA can phosphorylate a spectrum of substrates, potentially resulting in the enhancement of Spata31e5's functional activity. Another compound, IBMX, inhibits phosphodiesterases, causing an increase in cAMP and cGMP concentrations. Elevated levels of these cyclic nucleotides enhance the activity of PKA and protein kinase G (PKG), which may indirectly lead to the enhancement of Spata31e5's function via phosphorylation of proteins within the same pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP and cGMP levels in cells. This elevation can enhance PKA and PKG activity, respectively, which may indirectly increase the functional activity of Spata31e5 by modulating the phosphorylation status of related proteins. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is an activator of protein kinase C (PKC), which can potentiate various signaling cascades. Activation of PKC can lead to downstream effects that enhance the activity of proteins associated with Spata31e5's pathway. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentrations, potentially activating calcium-dependent proteins and signaling pathways that can enhance the activity of Spata31e5-related proteins. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is another calcium ionophore, which similarly to ionomycin, raises intracellular calcium levels, potentially leading to the activation of calcium-dependent signaling mechanisms that enhance the activity of Spata31e5. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which indirectly affects downstream signaling pathways such as Akt. This modulation can influence associated signaling cascades that enhance the functional activity of Spata31e5. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that can influence cytoskeletal dynamics. By altering the actin cytoskeleton, it may affect signaling pathways or cellular processes that enhance the functional activity of Spata31e5. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Blebbistatin is an inhibitor of myosin II ATPase activity, leading to alterations in cytoskeletal dynamics. This can influence cellular signaling pathways that may enhance the activity of Spata31e5. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor that can affect the MAPK/ERK pathway. By modulating this pathway, it could influence cellular processes that enhance the activity of Spata31e5. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could alter stress response pathways. This modulation may affect cellular processes that enhance the activity of Spata31e5. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which influences the c-Jun N-terminal kinase pathway. Modulation of this pathway could lead to cellular changes that enhance the functional activity of Spata31e5. | ||||||